Analysts expect Agile Therapeutics Inc (NASDAQ:AGRX) to report earnings per share of ($0.11) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.13). Agile Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 47.6%. The firm is scheduled to issue its next earnings results on Monday, May 6th.

On average, analysts expect that Agile Therapeutics will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.66) to ($0.34). For the next fiscal year, analysts forecast that the company will post earnings of ($0.48) per share, with EPS estimates ranging from ($0.79) to $0.11. Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04.

Several analysts have recently commented on AGRX shares. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Agile Therapeutics in a research note on Friday, January 11th. Maxim Group started coverage on shares of Agile Therapeutics in a research note on Thursday, November 29th. They issued a “buy” rating and a $3.00 target price for the company. Finally, ValuEngine upgraded shares of Agile Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, March 11th.

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in shares of Agile Therapeutics by 24.0% in the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the period. BlackRock Inc. lifted its stake in shares of Agile Therapeutics by 15.7% in the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock valued at $180,000 after purchasing an additional 226,255 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock valued at $449,000 after purchasing an additional 430,907 shares during the period. Finally, Fosun International Ltd acquired a new stake in shares of Agile Therapeutics in the third quarter valued at about $180,000. Institutional investors own 42.15% of the company’s stock.

AGRX stock opened at $1.61 on Tuesday. Agile Therapeutics has a one year low of $0.23 and a one year high of $3.24. The firm has a market capitalization of $57.41 million, a PE ratio of -2.78 and a beta of 0.36.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Article: What causes a recession?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.